Lao, Patrick
Edwards, Natalie
Flores-Aguilar, Lisi
Alshikho, Mohamad
Rizvi, Batool
Tudorascu, Dana
Rosas, H. Diana
Yassa, Michael
Christian, Bradley T.
Mapstone, Mark
Handen, Benjamin
Zimmerman, Molly E.
Gutierrez, Jose
Wilcock, Donna
Head, Elizabeth
Brickman, Adam M.
Funding for this research was provided by:
National Institutes of Health (RF1 AG079519, RF1 AG079519, RF1 AG079519, U01 AG051412, U19 AG068054, U19 AG068054, U19 AG068054, U19 AG068054, U19 AG068054, U19 AG068054, U19 AG068054, U19 AG068054, U19 AG068054, RF1 AG079519, RF1 AG079519, RF1 AG079519)
Article History
Received: 13 February 2024
Accepted: 13 May 2024
First Online: 29 May 2024
Competing interests
: Michael A. Yassa has received consulting fees from Eisai Cognito Therapeutics, LLC, CuraSen Therapeutics, Inc, and Enthorin Therapeutics, LLC. Adam Brickman receives compensation for consultation to Cognition Therapeutics and Cognito Therapeutics and for his role on the Scientific Advisory Board of CogState. He is an inventor a patent for white matter hyperintensity quantification (US Patent US9867566B2) and serves on a Data Safety Monitoring Board for University of Illinois, Urbana-Champaign. All other authors do not have competing interests to declare.